Press Releases

Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors

May 17, 2019
Cristal Therapeutics, a clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and...
Read more
Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors

InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy

May 15, 2019
- Journal of Neuroscience publication demonstrates that antagonizing miR-135a reduces seizures in chronic TLE model -
Read more
InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy

A One-Two Punch for HPV-16-positive Cancers? 30 Apr 2019

April 30, 2019
ISA's phase 2 trial with lead product ISA101
Read more
A One-Two Punch for HPV-16-positive Cancers? 30 Apr 2019

Video interview with ISA CSO Prof. Dr. Cornelis Melief at AACR 2019

April 18, 2019
ecancer interview ISA's Chief Science Officer Prof. Dr. Kees Melief
Read more
Video interview with ISA CSO Prof. Dr. Cornelis Melief at AACR 2019

CRI Speaks with 2019 AACR-CRI Lloyd J. Old Award Recipient, Dr. Cornelis 'Kees' Melief

April 02, 2019
Cornelis J. M. 'Kees' Melief, M.D., Ph.D., received the 2019 AACR-CRI Lloyd J. Old Award in Cancer Immunology presented by the...
Read more
CRI Speaks with 2019 AACR-CRI Lloyd J. Old Award Recipient, Dr. Cornelis 'Kees' Melief

ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019

March 28, 2019
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
Read more
ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019

InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board

March 25, 2019
--Co-inventor of original CTLA4-antibody and immuno-oncology innovator to expand the Company's clinical development expertise--...
Read more
InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board

Modra Pharmaceuticals announces first patients treated in phase IIa metastatic breast cancer trial

March 21, 2019
Drug Name : docetaxel + ritonavir
Read more
Modra Pharmaceuticals announces first patients treated in phase IIa metastatic breast cancer trial

ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019

March 19, 2019
- Recognition for outstanding and innovative cancer research
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019

Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers

February 20, 2019
Sapreme Technologies has been awarded a 6.8 M€ grant by the European Union.
Read more
Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers

Modra Pharmaceuticals Expands Management Team and Provides Corporate Update

December 19, 2018
-- Colin Freund has joined as CEO -- Dr. Edwin De Wit appointed Head of Oncology Development -- Dr. Alan Barge appointed Chai...
Read more
Modra Pharmaceuticals Expands Management Team and Provides Corporate Update

ISA Pharmaceuticals' Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018

November 13, 2018
Leiden, The Netherlands, November 13, 2018 - ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announce...
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018

Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline

November 02, 2018
Maastricht, The Netherlands, 2nd November 2018 - Cristal Therapeutics, a clinical stage pharmaceutical company developing targ...
Read more
Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline

Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer

October 24, 2018
Maastricht, The Netherlands, 25th October 2018 - Cristal Therapeutics, a clinical stage pharmaceutical company developing uniqu...
Read more
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer

InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting

October 01, 2018
--Two poster presentations highlight INT-1B3's immune-system activation and CD8+ T cell-driven anti-tumor response in addition...
Read more
InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting

Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board

September 10, 2018
10th September 2018, Windsor, UK: Macrophage Pharma Limited ('MPL'), a company focused on the discovery and development of next...
Read more
Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board

Inthera Bioscience AG expands management team with seasoned professionals and secures €4.7 million second tranche of €9.6 million Series A financing

June 26, 2018
Wädenswil, Switzerland, June 6th, 2018 Inthera Bioscience AG, a pre-clinical stage oncology company targeting the inhibition...
Read more
Inthera Bioscience AG expands management team with seasoned professionals and secures €4.7 million second tranche of €9.6 million Series A financing

InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting

April 18, 2018
--INT-1B3 targets multiple hallmarks of cancer as a single agent resulting in immune-system activation, tumor regression and pr...
Read more
InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting

Macrophage Pharma Appoints Dr Michael Moore as Chairman

April 11, 2018
11 April 2018, Windsor, UK: Macrophage Pharma Limited ('MPL'), a company focused on the discovery and development of next-gener...
Read more
Macrophage Pharma Appoints Dr Michael Moore as Chairman

MIMETAS Secures 20 Million Dollar Series B Financing

April 11, 2018
Global leader in organ-on-a-chip technology backed by international syndicate for worldwide commercial expansion and new produc...
Read more
MIMETAS Secures 20 Million Dollar Series B Financing
1 2 3 4 Next

Home > Press Releases > Archive

© 2020 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds